WorkJuly 15, 2026via TechCrunch AI
OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B
Why it matters
Top AI researcher departure signals talent drain from labs to specialized AI applications. Validates investor thesis that AI's highest-ROI use cases lie in biotech, not consumer chat.
Key signals
- Miles Wang (OpenAI researcher) launching new startup
- $2B valuation in funding discussions
- Focus: AI drug discovery / life sciences applications
- Signals investor appetite for AI-biotech vertical plays
- Key talent migration from foundational model labs to domain-specific applications
The hook
$2B. That's the valuation for Miles Wang's AI drug discovery startup—and he's leaving OpenAI to build it.
The funding discussions point to investor interest in applying AI to make breakthroughs in life sciences.